Literature DB >> 32641520

Cerebrovascular reactivity in cerebral amyloid angiopathy, Alzheimer disease, and mild cognitive impairment.

Aaron R Switzer1, Ikreet Cheema1, Cheryl R McCreary1, Angela Zwiers1, Anna Charlton1, Ana Alvarez-Veronesi1, Ramnik Sekhon1, Charlotte Zerna1, Randall B Stafford1, Richard Frayne1, Bradley G Goodyear1, Eric E Smith2.   

Abstract

OBJECTIVE: To assess cerebrovascular reactivity in response to a visual task in participants with cerebral amyloid angiopathy (CAA), Alzheimer disease (AD), and mild cognitive impairment (MCI) using fMRI.
METHODS: This prospective cohort study included 40 patients with CAA, 22 with AD, 27 with MCI, and 25 healthy controls. Each participant underwent a visual fMRI task using a contrast-reversing checkerboard stimulus. Visual evoked potentials (VEPs) were used to compare visual cortex neuronal activity in 83 participants. General linear models using least-squares means, adjusted for multiple comparisons with the Tukey test, were used to estimate mean blood oxygen level-dependent (BOLD) signal change during the task and VEP differences between groups.
RESULTS: After adjustment for age and hypertension, estimated mean BOLD response amplitude was as follows: CAA 1.88% (95% confidence interval [CI] 1.60%-2.15%), AD 2.26% (1.91%-2.61%), MCI 2.15% (1.84%-2.46%), and control 2.65% (2.29%-3.00%). Only patients with CAA differed from controls (p = 0.01). In the subset with VEPs, group was not associated with prolonged latencies or lower amplitudes. Lower BOLD amplitude response was associated with higher white matter hyperintensity (WMH) volumes in CAA (for each 0.1% lower BOLD response amplitude, the WMH volume was 9.2% higher, 95% CI 6.0%-12.4%) but not other groups (p = 0.002 for interaction) when controlling for age and hypertension.
CONCLUSIONS: Mean visual BOLD response amplitude was lowest in participants with CAA compared to controls, without differences in VEP latencies and amplitudes. This suggests that the impaired visual BOLD response is due to reduced vascular reactivity in CAA. In contrast to participants with CAA, the visual BOLD response amplitude did not differ between those with AD or MCI and controls.
© 2020 American Academy of Neurology.

Entities:  

Mesh:

Year:  2020        PMID: 32641520      PMCID: PMC7538216          DOI: 10.1212/WNL.0000000000010201

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  46 in total

1.  Temporal autocorrelation in univariate linear modeling of FMRI data.

Authors:  M W Woolrich; B D Ripley; M Brady; S M Smith
Journal:  Neuroimage       Date:  2001-12       Impact factor: 6.556

2.  The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Marilyn S Albert; Steven T DeKosky; Dennis Dickson; Bruno Dubois; Howard H Feldman; Nick C Fox; Anthony Gamst; David M Holtzman; William J Jagust; Ronald C Petersen; Peter J Snyder; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

Review 3.  The clinical role of evoked potentials.

Authors:  P Walsh; N Kane; S Butler
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-06       Impact factor: 10.154

4.  Guideline 9B: Guidelines on visual evoked potentials.

Authors: 
Journal:  J Clin Neurophysiol       Date:  2006-04       Impact factor: 2.177

5.  Cerebrovascular function in presymptomatic and symptomatic individuals with hereditary cerebral amyloid angiopathy: a case-control study.

Authors:  Anna M van Opstal; Sanneke van Rooden; Thijs van Harten; Eidrees Ghariq; Gerda Labadie; Panagiotis Fotiadis; M Edip Gurol; Gisela M Terwindt; Marieke J H Wermer; Mark A van Buchem; Steven M Greenberg; Jeroen van der Grond
Journal:  Lancet Neurol       Date:  2016-12-16       Impact factor: 44.182

6.  Altered cerebrovascular reactivity velocity in mild cognitive impairment and Alzheimer's disease.

Authors:  Jonas Richiardi; Andreas U Monsch; Tanja Haas; Frederik Barkhof; Dimitri Van de Ville; Ernst W Radü; Reto W Kressig; Sven Haller
Journal:  Neurobiol Aging       Date:  2014-07-24       Impact factor: 4.673

7.  Assessment of older people: self-maintaining and instrumental activities of daily living.

Authors:  M P Lawton; E M Brody
Journal:  Gerontologist       Date:  1969

Review 8.  Cerebrovascular hemodynamics in Alzheimer's disease and vascular dementia: a meta-analysis of transcranial Doppler studies.

Authors:  Behnam Sabayan; Steffy Jansen; Anna M Oleksik; Matthias J P van Osch; Mark A van Buchem; Peter van Vliet; Anton J M de Craen; Rudi G J Westendorp
Journal:  Ageing Res Rev       Date:  2011-12-27       Impact factor: 10.895

Review 9.  Cerebral microbleeds: overview and implications in cognitive impairment.

Authors:  Sergi Martinez-Ramirez; Steven M Greenberg; Anand Viswanathan
Journal:  Alzheimers Res Ther       Date:  2014-06-11       Impact factor: 6.982

10.  Application of calibrated fMRI in Alzheimer's disease.

Authors:  Isabelle Lajoie; Scott Nugent; Clément Debacker; Kenneth Dyson; Felipe B Tancredi; AmanPreet Badhwar; Sylvie Belleville; Yan Deschaintre; Pierre Bellec; Julien Doyon; Christian Bocti; Serge Gauthier; Douglas Arnold; Marie-Jeanne Kergoat; Howard Chertkow; Oury Monchi; Richard D Hoge
Journal:  Neuroimage Clin       Date:  2017-05-16       Impact factor: 4.881

View more
  2 in total

1.  Vascular Risk Factors, Imaging, and Outcomes in Transient Ischemic Attack/Ischemic Stroke Patients with Neuroimaging Evidence of Probable/Possible Cerebral Amyloid Angiopathy.

Authors:  Qihui Zhang; Anxin Wang; Xia Meng; Xiaoling Liao; Yijun Zhang; Huiqing Hou; Lijuan Niu; Ruiping Li; Wenjuan Guo; Yongjun Wang
Journal:  Oxid Med Cell Longev       Date:  2021-04-26       Impact factor: 6.543

2.  Cerebrovascular Reactivity Across the Entire Brain in Cerebral Amyloid Angiopathy.

Authors:  Andrew E Beaudin; Cheryl R McCreary; Erin L Mazerolle; Myrlene Gee; Breni Sharma; Arsenije Subotic; Angela M Zwiers; Emily Cox; Krista Nelles; Anna Charlton; Richard Frayne; Zahinoor Ismail; Christian Beaulieu; Glen C Jickling; Richard M Camicioli; G Bruce Pike; Eric E Smith
Journal:  Neurology       Date:  2022-02-24       Impact factor: 11.800

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.